Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 15/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CALCA | P06881 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313770 | 0.94 | CALCRL (0.46) | CALCRLRAMP1CYP3A4CHRM2CHRM4 | |
| SCHEMBL14540246 | 0.91 | CALCRL (0.38) | CALCRLRAMP1CYP3A4CHRM2CHRM4 | |
| SCHEMBL14540244 | 0.89 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL13313769 | 0.88 | CALCRL (0.53) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL3524613 | 0.87 | CALCRL (0.55) | CALCRLRAMP1CYP3A4CHRM2CHRM4 | |
| SCHEMBL3524610 | 0.87 | CALCRL (0.55) | CALCRLRAMP1CYP3A4CHRM2CHRM4 | |
| SCHEMBL13313780 | 0.86 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL13313775 | 0.86 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL13313776 | 0.80 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CHRM2CHRM4 | |
| SCHEMBL13313777 | 0.80 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1770091-A1 | CGRP-antagonists, process for their preparation as well as their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |